Janssen, owned by Johnson & Johnson, has received approval from the European Commission to market Darzalex in combination with excipients for the treatment of two different diseases. The first combination of Darzalex with bortezomib, cyclophosphamide and dexamethasone is used to treat early stage mild chain amyloidosis in adults. The second combination with pomalidomide and dexamethasone for the treatment of adults with multiple myeloma.